Tags

Type your tag names separated by a space and hit enter

[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].

Abstract

Spasticity remains a prevalent symptom in multiple sclerosis, with a significant associated disability and quality of life impairment. A significant improvement in therapy aimed at reducing multiple sclerosis relapses and modifying its course has been achieved in recent years. Both general and specific traditional treatments have, however, major limitations. Thus, its use in real practice is lower than expected. Cannabinoids provide a new way for therapy. A delta-9-tetrahydrocannabinol plus cannabidiol (1:1) association, administered through an oromucosal route, has been approved in several countries including Spain; it causes a specific effect on CB(1) and CB(2) receptors, with traditional psychotropic cannabis actions being minimized. Randomized, placebo-controlled trials, as well as longer-term open-label extensions, have shown a clear-cut efficacy to reduce spasticity and their associated symptoms in those patients refractory to other therapies, with a good tolerability/safety profile. No tolerance, abuse or addictive issues have been found. New studies will be needed to find out potential new cannabinoid-related therapies.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    Unidad de Esclerosis Múltiple, Servicio de Neurología, Hospital Clínico San Carlos, IdISSC, Madrid, España. orejacbn@gmail.com

    Source

    Revista de neurologia 55:7 2012 Oct 01 pg 421-30

    MeSH

    Administration, Sublingual
    Cannabidiol
    Clinical Trials, Phase III as Topic
    Double-Blind Method
    Dronabinol
    Drug Combinations
    Humans
    Legislation, Drug
    Multicenter Studies as Topic
    Multiple Sclerosis
    Muscle Spasticity
    Parasympatholytics
    Plant Extracts
    Powders
    Randomized Controlled Trials as Topic
    Receptor, Cannabinoid, CB1
    Receptor, Cannabinoid, CB2
    Retrospective Studies
    Spain
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Review

    Language

    spa

    PubMed ID

    23011861

    Citation

    Oreja-Guevara, Celia. "[Treatment of Spasticity in Multiple Sclerosis: New Perspectives Regarding the Use of Cannabinoids]." Revista De Neurologia, vol. 55, no. 7, 2012, pp. 421-30.
    Oreja-Guevara C. [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids]. Rev Neurol. 2012;55(7):421-30.
    Oreja-Guevara, C. (2012). [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids]. Revista De Neurologia, 55(7), pp. 421-30.
    Oreja-Guevara C. [Treatment of Spasticity in Multiple Sclerosis: New Perspectives Regarding the Use of Cannabinoids]. Rev Neurol. 2012 Oct 1;55(7):421-30. PubMed PMID: 23011861.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids]. A1 - Oreja-Guevara,Celia, PY - 2012/9/27/entrez PY - 2012/9/27/pubmed PY - 2013/4/6/medline SP - 421 EP - 30 JF - Revista de neurologia JO - Rev Neurol VL - 55 IS - 7 N2 - Spasticity remains a prevalent symptom in multiple sclerosis, with a significant associated disability and quality of life impairment. A significant improvement in therapy aimed at reducing multiple sclerosis relapses and modifying its course has been achieved in recent years. Both general and specific traditional treatments have, however, major limitations. Thus, its use in real practice is lower than expected. Cannabinoids provide a new way for therapy. A delta-9-tetrahydrocannabinol plus cannabidiol (1:1) association, administered through an oromucosal route, has been approved in several countries including Spain; it causes a specific effect on CB(1) and CB(2) receptors, with traditional psychotropic cannabis actions being minimized. Randomized, placebo-controlled trials, as well as longer-term open-label extensions, have shown a clear-cut efficacy to reduce spasticity and their associated symptoms in those patients refractory to other therapies, with a good tolerability/safety profile. No tolerance, abuse or addictive issues have been found. New studies will be needed to find out potential new cannabinoid-related therapies. SN - 1576-6578 UR - https://www.unboundmedicine.com/medline/citation/23011861/[Treatment_of_spasticity_in_multiple_sclerosis:_new_perspectives_regarding_the_use_of_cannabinoids]_ L2 - http://www.revneurol.com/LinkOut/formMedLine.asp?Refer=2012362&Revista=RevNeurol DB - PRIME DP - Unbound Medicine ER -